• Opinion
• [Reporter’s View] Bitter ERPs following spin-offs and sales
• by Eo, Yun-Ho May 17, 2023 05:38am

• Company
• Hemophilia drug Hemlibra coverage expansion
• by Chon, Seung-Hyun May 17, 2023 05:37am

• Policy
• Patent protection for 42 yrs for Humira/32 yrs for Keytruda
• by Lee, Hye-Kyung May 16, 2023 09:07pm

• Company
• Crysvita, the first fast-track drug by Yoon gov, is expected
• by Eo, Yun-Ho May 16, 2023 09:06pm

• Company
• JAKi Cibinqo owns strengths in dosage adjustments
• by Jung, Sae-Im May 16, 2023 05:40am

• Opinion
• [Reporter's view] AI drug development, should face reality
• by Hwang, Jin-joon May 16, 2023 05:39am

• Company
• Samil, a series of love calls from multinational companies
• by Lee, Seok-Jun May 16, 2023 12:16am

• Policy
• Biopharmaceutical CDMO annual average of ↑31%
• by Lee, Hye-Kyung May 15, 2023 05:41am

• Company
• New diabetes treatment guidelines released
• by Kim, Jin-Gu May 15, 2023 05:41am

• InterView
• ‘Even a 0.2 vision is a miracle to some’
• by Eo, Yun-Ho May 15, 2023 05:41am